Slide 1: Seeing Beyond Today
Exhibit 99.1 Seeing Beyond Today
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially. This presentation is being made on September 11, 2006, and Alcon does not unde
Slide 3: Worldwide Leader in Eye Care
Worldwide Leader in Eye Care Sales $4.4 billion in 2005 Scope 12,700 total employees 2,800 person sales force 75 local operating companies 60 physician training centers Share #1 or #2 position in main segments #1 share in most product categories Science $2.5 billion planned R&D investment over next
Slide 4: Long-Term Financial Execution
Long-Term Financial Execution Revenue Net Income $5,000 $1,200 % 11 .3% 28.0 G R= 10.6% = 1,139 -05 C A ncy = GR $4,000 2000 ur re 4,369 $1,000 CA 39.9% nt C - 05 s t a 00 Con 3,914 11.6% $800 20 $3,000 3,407 14.9% 814 3,009 13.2% 36.7% 2,748 $600 9.5% 595 $2,000 7.6% 489 21.8% $400 362 35.0% $1,000
Slide 5: Continued Growth Q2 YTD
Continued Growth Q2 YTD $3,000 +10.1% 2005 2006 $2,500 $2,467.9 $2,000 $2,242.5 $1,500 $1,000 +21.4% $500 $697.4 $574.5 $0 Revenue Net Income* * Non-GAAP adjusted Net Income – See appendix for reconciliation 5
Slide 6: Enhancing Leadership Through Research
Enhancing Leadership Through Research 500 450 422 390 $ Millions Per Year 400 350 350 323 290 300 246 250 213 200 150 100 50 0 1999 2000 2001 2002 2003 2004 2005 6
Slide 7: Alcon R&D Strategic Principles
Alcon R&D Strategic Principles Consumer 7% • Develop new products differentiated from our competitors through innovation Pharma Surgical • Invest appropriate to market 60% 33% opportunity • Blend internal research with external licensing and partnering • Pharmaceutical 15 – 17% of Sales • Surgical 8
Slide 8: Expanding Research Collaborations
Expanding Research Collaborations Glaucoma Retina Allergy/Dry Eye Abbott Albany Molecular Amgen Dharmacon Jerini AG Kalypsys Origenis AG 8
Slide 9: 2006 Launches Adding to Growth
2006 Launches Adding to Growth DuoTravTM Systane® Liquid Gel (EU) (US) OPTI-FREE® RepleniSH® LADAR6000TM (US) (US) AcrySert® OZilTM (JP) (US/EU) AcrySof® Natural VegamoxTM (JP) Pending (JP) AcrySof® Toric (US) Patanol® (JP) 9
Slide 10: New Technologies Support Market Share and Gains
New Technologies Support Market Share and Gains U.S. Unit Market Shares 100% 75% 2003 50% 2004 51% 54% 55% 49% 2005 2006 YTD 25% 0% IOL's SOURCE: Alcon Data on File 10
Slide 11: Cataract Share Leader in Hospitals and ASCs
Cataract Share Leader in Hospitals and ASCs 80% IOL Market Share by Class of Trade (YTD) --ASC IOL Shares (1Q06)-- 70% 60% 50% Alcon AMO 40% B&L 30% Other 20% 10% 0% Total Market Hospital ASC SOURCE: Market Scope Annual Cataract Surgeon Report (August 2006) 11
Slide 12: NTIOL Status is Increasing Use of Aspheric IOLs
NTIOL Status is Increasing Use of Aspheric IOLs Penetration of Aspheric Monofocal IOLs (% of procedures) 100% 75% 50% 25% 33% 38% 0% Q1 2006 Q2 2006 SOURCE: Market Scope Cataract Quarterly Update (August 2006) Aspheric Mono-Focal IOLs All Other IOLs 12
Slide 13: Alcon Maintains Dominant Aspheric IOL Market Share
Alcon Maintains Dominant Aspheric IOL Market Share Aspheric IOL Use by Manufacturer (% of procedures) 11% 5% 100% 17% 19% 75% 50% 65% 61% 25% 0% Q1 2006 Q2 2006 SOURCE: Market Scope Alcon AMO B&L Cataract Quarterly Update (August 2006) 13
Slide 14: More Surgeons Use ReSTOR than Any Other Brand of PC-IOL
More Surgeons Use ReSTOR than Any Other Brand of PC-IOL % of Surgeons Using PC-IOLs by Brand ReSTOR 91% ReZoom 35% CrystaLens 27% 0% 20% 40% 60% 80% 100% SOURCE: Market Scope Annual Cataract Surgeon Report (June 2006) 14
Slide 15: Vast Majority of Physicians Implant ReSTOR Bilaterally
Vast Majority of Physicians Implant ReSTOR® Bilaterally % of Physicians Using Mix & Match by Brand 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% ReSTOR ReZoom CrystaLens % of Surgeons Using 91% 35% 27% Mix & Match Bilateral SOURCE: Market Scope Annual Cataract Surgeon Report (June 2006) 15
Slide 16: Near Term Challenges to Adoption and Penetration
Near Term Challenges to Adoption and Penetration • Predominantly cataract U.S. Surgeon Segmentation surgeons unlikely to embrace LVC for PC-IOLs 1,500 • Predominantly Cataract surgeons will move into this 1,500 market when the presbyopia 5,500 correcting IOL can help them manage astigmatism and othe
Slide 17: AcrySof Toric Opportunity Has Significant Potential
AcrySof® Toric Opportunity Has Significant Potential Surgeons Using Toric Lenses Expected IOL Brand Preference 100 9% 75 65% 50 91% 25 13% Acrysof Toric Staar Toric 0 Current Use Future Use SOURCE: Alcon Data on File 17
Slide 18: Infiniti is Upgrading and Converting Surgeons
Infiniti® is Upgrading and Converting Surgeons Planning to Acquire New Phaco in the Next 12 Months 100% (% of US surgeons) Primary System Consideration (% of of US surgeons) 75% 64% YES 23% 50% 25% 0% Millennium Infiniti Other Compact Alcon Sovereign and Lomb Bausch AMO AMO SOURCE: Market Scope: Ann
Slide 19: OZil Torsional Technology Differentiates Infiniti
OZil™ Torsional Technology Differentiates Infiniti® Performance Ratings (Scale 1-10) (% of US surgeons indicating 9 or 10) • The OZil™ torsional hand Improve 71% piece is a leap in lens Patient removal technology Outcomes • OZil™ is a proprietary, 79% Increase patented technology which Surgical Effi
Slide 20: EURMEA Glaucoma Market
EURMEA Glaucoma Market $US 1.27 Billion A lp ha A g o nist s 6% Ot her Market in 2005 T C A IS 7% 11% N o n- PG C o mb o s B et a B lo cker s 8% 3 7% PG C o mb o s 2003-2010E CAGR 4% Total Glaucoma 3.9% Prostaglandins 7.2% Pr o st ag land i ns 2 7% Prostaglandin 22.2% Combos (Source: Internal estima
Slide 21: Patanol in Japan
Patanol® in Japan US$ 200 million Market Multi- action 14% • January to March – Mountain Cedar • Anti-histamine, Livostin (Santen) is Anti- Mast Cell current market leader with 25% share histamine Stabilizers • Mast Cell Stabilizers led by Intal 25% 61% (Astellas) & Rizaben (Kissei) • Zaditen (Novar
Slide 22: Vegamox in Japan
VegamoxTM in Japan • Large and developed market – Approximately US$ 200 million – Extended course of therapy post-surgery - up to 6 months – 80% converted to fluoroquinolones – Lead products by Japanese firms dominate market • Santen (Cravit & Taravid) • Senju (Gatiflo) – Flat to declining growth du
Slide 23: RepleniSH Driving Opti-Free Gains
RepleniSHTM Driving Opti-Free® Gains U.S. Share of Branded Disinfectants 50% 40% Renu* OPTI-FREE® 30% RepleniSH launch 20% 10% Complete* Fusarium Outbreak 0% 6 6 6 6 6 6 5 5 06 /0 /0 /0 /0 /0 /0 /0 /0 8/ 21 18 18 15 13 10 6 4 7/ /2 /2 1/ 2/ 3/ 4/ 5/ 6/ 11 12 * Renu is a registered trademark of Bausc
Slide 24: Future Opportunity
Future Opportunity U.S. Pipeline Pharmaceutical Travatan® BAC Free Glaucoma Filed (2006) RETAANE® Wet AMD Amending (2008+) 15(S) HETE Dry Eye Phase III (2008+) Rimexolone Dry Eye Phase II (2008+) Moxifloxacin/Dexamethasone Anti-infective/anti-inflammatory Phase II (2008+) Moxifloxacin, new formulati
Slide 25: Sustaining Eye Care Market Leadership
Sustaining Eye Care Market Leadership • Maintain business focus on eye care • Capitalize on global infrastructure to gain operating synergies and expand presence in emerging markets • Deliver strong and consistent financial performance • Build core brands on global basis • Increase R&D investment in
Slide 26: Appendix: Non-GAAP Adjustments
Appendix: Non-GAAP Adjustments Non-GAAP Reported Adjustment Adjusted 2002 Operating Profit 703.7 42.5 746.2 Op Profit Growth 19.5% 26.7% Expense for employee deferred Net Income 466.9 21.8 488.7 comp, SKBM recall, and IPO Net Income Growth 47.9% 35.1% proceeds effect in interest expense Fully Dilute
Slide 27: Appendix: Non-GAAP Adjustments
Appendix: Non-GAAP Adjustments Non-GAAP Reported Adjustment Adjusted June 2006 YTD Gross Profit 1,854.4 5.8 1,860.2 Gross Profit Margin 75.1% 75.4% Operating Profit 918.2 (69.6) 848.6 Settlement of AMO lawsuit and Op Profit Growth 23.0% 13.7% removal of share-based Net Income 761.3 (63.9) 697.4 comp